Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy.

Published in:

PLoS ONE, 2022, v. 17, n. 11, p. 1, doi. 10.1371/journal.pone.0276462

By:

• Kadam, Anil H.;
• Kandasamy, Kathirvel;
• Buss, Tim;
• Cederstrom, Brittany;
• Yang, Chun;
• Narayanapillai, Sreekanth;
• Rodriguez, Juan;
• Levin, Michael D.;
• Koziol, Jim;
• Olenyuk, Bogdan;
• Borok, Zea;
• Chrastina, Adrian;
• Schnitzer, Jan E.

Publication type:

Article